Thomas A Cooper Selected Research

Myotonic Dystrophy (Dystrophia Myotonica)

1/2021	Reversible cardiac disease features in an inducible CUG repeat RNA-expressing mouse model of myotonic dystrophy.
1/2020	Aberrant Expression of a Non-muscle RBFOX2 Isoform Triggers Cardiac Conduction Defects in Myotonic Dystrophy.
12/2019	Endurance exercise leads to beneficial molecular and physiological effects in a mouse model of myotonic dystrophy type 1.
10/2018	CRISPR -Mediated Expression of the Fetal Scn5a Isoform in Adult Mice Causes Conduction Defects and Arrhythmias.
1/2018	Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1.
10/2017	BNANC Gapmers Revert Splicing and Reduce RNA Foci with Low Toxicity in Myotonic Dystrophy Cells.
6/2015	Antagonistic regulation of mRNA expression and splicing by CELF and MBNL proteins.
1/2014	The Mef2 transcription network is disrupted in myotonic dystrophy heart tissue, dramatically altering miRNA and mRNA expression.
8/2013	Reexpression of pyruvate kinase M2 in type 1 myofibers correlates with altered glucose metabolism in myotonic dystrophy.
5/2013	Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas A Cooper Research Topics

Disease

25	Myotonic Dystrophy (Dystrophia Myotonica) 01/2021 - 07/2002
4	Neoplasms (Cancer) 09/2015 - 03/2011
2	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 03/2015 - 01/2006
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 10/2007 - 07/2005
1	Heart Diseases (Heart Disease) 01/2021
1	Cardiac Conduction System Disease 01/2020
1	Cardiac Arrhythmias (Arrythmia) 01/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 07/2015
1	Eye Diseases (Eye Disease) 07/2015
1	Glaucoma 07/2015
1	Optic Atrophy 07/2015
1	Retinal Degeneration 07/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2015
1	Proteostasis Deficiencies 03/2015
1	Fibrosis (Cirrhosis) 01/2014
1	Muscular Dystrophies (Muscular Dystrophy) 04/2011
1	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 04/2011
1	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 04/2011
1	Myotonia 02/2008
1	Channelopathies 04/2007
1	Spinocerebellar Ataxia 10 01/2006
1	Huntington Disease (Huntington's Disease) 01/2006
1	Fragile X Tremor Ataxia Syndrome 01/2006
1	Cardiomegaly (Heart Hypertrophy) 07/2005
1	Cardiomyopathies (Cardiomyopathy) 01/2005

Drug/Important Bio-Agent (IBA)

12	RNA (Ribonucleic Acid)IBA 01/2021 - 06/2005
9	3' Untranslated Regions (3' UTR)IBA 12/2019 - 07/2002
7	Proteins (Proteins, Gene)FDA Link 09/2015 - 04/2003
6	Protein Kinases (Protein Kinase)IBA 12/2019 - 07/2005
4	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2020 - 01/2006
3	Protein Isoforms (Isoforms)IBA 01/2020 - 08/2013
2	MicroRNAs (MicroRNA)IBA 01/2020 - 01/2014
2	Pharmaceutical PreparationsIBA 05/2014 - 03/2011
2	Myotonin-Protein KinaseIBA 10/2007 - 01/2006
1	RNA Splicing FactorsIBA 01/2020
1	Tetracycline (Achromycin)FDA LinkGeneric 01/2020
1	Rhodopsin (Visual Purple)IBA 07/2015
1	Mutant Proteins (Protein, Mutant)IBA 03/2015
1	Messenger RNA (mRNA)IBA 01/2014
1	Pyruvate KinaseIBA 08/2013
1	EnzymesIBA 08/2013
1	Glucose (Dextrose)FDA LinkGeneric 08/2013
1	Antisense OligonucleotidesIBA 05/2013
1	Untranslated Regions (Untranslated Region)IBA 05/2013
1	Ribonuclease H (RNase H)IBA 03/2012
1	NeurotoxinsIBA 04/2011
1	CardiotoxinsIBA 04/2011
1	notexinIBA 04/2011
1	Laminin (Merosin)IBA 04/2011
1	NucleotidesIBA 12/2009
1	CELF1 ProteinIBA 02/2008
1	ChloridesIBA 04/2007
1	ActininIBA 04/2003
1	Chloride Channels (Chloride Channel)IBA 07/2002

Therapy/Procedure

1	Therapeutics 09/2011
1	Heterologous Transplantation (Xenotransplantation) 03/2011